NBRP研究用ヒト臍帯血細胞バンク事業のパンフレットはこちらから (English version.)


研究用臍帯血の利用状況に関する調査報告書はこちら

研究内容

  • 検査部・輸血部における検査技術や品質向上を目指した研究に関するお知らせ
  • Department of Cell Processing and Transfusion
    セルプロセッシング・輸血部


     Associate Professor Tokiko Nagamura-Inoue, M.D., D.M.Sc.
      准教授 医学博士  長村登紀子
     Assistant Profissor Toyotaka Kawamata, M.D., D.M.Sc.
      助教  医学博士  川俣 豊隆
     Post-dcotoral fellow Mayuko Tsuda, M.D., D.M.Sc.
      医員  医学博士  津田 真由子

     Our department was established in 1990, in order to manage the transfusion medicine and the cell processing for hematopoietic stem cell transplantation. Beside the transfusion medicine and testing in the hospital, our department has been supported translational research and managed IMSUT-Cell Resource Center (IMSUT-CRC), which has been established in 1997. Recent our projects include Research CB Stem Cells Bank as National Bioresource Project (NBRP) supported by AMED(MEXT) and CB and umbilical cord (UC)-derived mesenchymal stem/stromal cell banking (IMSUT CORD) for clinical use supported by AMED(MHLW). In this stdy, we developed immunosuppressive therapy for severe GVHD after hematopoietic stem cell transplantation using UC-MSCs and expanded regulatory T cells from CB and adult blood. We also explore the clinical application of UC-MSC for newborn encephalopathy, some of which develop to cerebral palsy.


    1. Umbilical Cord-derived mesenchymal stem/stromal cells banking (IMSUT-CORD):
    Nagamura-Inoue T, Tsuda M. Mori Y, Takahashi A, Shimazu T, Mukai T, Tojo A.
    Umbilical cord (UC) is a rich source of mesenchymal stem cells (MSCs). The UC is normally discarded after birth and its collection does not require an invasive procedure with ethical concerns. Moreover, UC-derived MSCs (UC-MSCs) possess many advantageous features, namely high frequency, pluripotency, high proliferation capacity, immunomodulatory properties and no donor age-dependent variations. We have studied these characteristics and efficient expansion system of UC-MSCs, in order to apply the regenerative medicine and immunotherapy, supported by MHLW. UC-MSCs have the potential to inhibit the activated T cell proliferation upon the allogeneic stimulations, suggesting the clinical possibility to apply those for the GVHD treatment. Our final goal is to establish the CB and UC-MSCs banking for clinical use.
    2. Toward Investigator-sponsored IND (Investigation New Drug application) of allogeneic umbilical cord-derived mesenchymal stromal cells for severe acute graft-versus –host disease.
    Nagamura-Inoue T, Tsuda M. Mori Y, Takahashi A, Shimazu T, Mukai T, Tojo A.
    The present study aims, through a corporate collaboration, to process umbilical cord-derived mesenchymal stromal cells (UC-MSC) as a product for applications such as regenerative medicine, and perform an investigator-initiated clinical trial (phase I) against Grade III-IV severe acute graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation (HSCT). Severe acute GVHD negatively influences the prognosis of HSCT, where the long-term survival rate in cases of steroid resistance is extremely low. In 2015, bone marrow (BM)-derived MSCs were reported to be effective against the severe acute GVHD and were commercially introduced; however, these are derived from imported BM and are expensive. The UC-MSC proposed here are intrinsically adhesive, and have defined phenotypes of MSC and differentiation potency. Moreover, their traceability is high due to their domestic origin; harvesting them confers no physical burden on the donor; and they have high proliferative potential and alloimmune suppressive capacity. They also have low antigenicity, and because they are treated as medical waste, ethical obstacles are few and they can be easily and widely obtained. We were the first to report on UC-MSC of domestic origin, and we developed efficient MSC recovery methods and a serum-free cryoprotectant based on cord tissue cryopreservation and improved explant methods. Furthermore, by culturing with serum-free medium (RM medium; Rohto Pharmaceuticals), we achieved serum-free manufacture from harvest to cryopreservation. In 2016, through strategic pharmaceutical consultation with the Pharmaceuticals and Medical Devices Agency (PMDA), we reached an agreement not only regarding a clinical trial, but also regarding quality/safety, and aspects of production unrelated to the trial. Presently, although non-clinical safety tests and some virus testing are still ongoing, reports on these tests will soon be available, and we are scheduled to commence the investigator-initiated clinical trial within the 2017 fiscal year.
    3. Therapeutic potential of Umbilical cord-derived mesenchymal stromal cells to the cerebral palsy.
    Mukai T, Shimazu T, Mori Y, Takahashi A, Nagamura-Inoue T.
    Previous studies have been reported that MSCs have self-renewal capacity, multi-lineage differentiation potential and the ability to migrate toward sites of inflammation or injury. The potential of MSCs for transdifferentiating into not only mesoderm lineage but also endoderm and ectoderm, including the neural lineage, has enhanced the clinical application of MSCs for regenerative medicine including neurological disorders. We reported here that the umbilical cord-derived mesenchymal stromal cells (UC-MSCs) had the potential of neurogenic differentiation. Furthermore, the neurogenic lineage genes expressed more in differentiation via neurosphere formation with higher expresion of ES markers. The migration ability to damaged cells was not influenced by the neurosphere formation with or without differentiationinto neurogenic cells. Now newborn mice models mimicking cerebral palsy is under investigation. in vivo.
    4. Expansion of regulatory T cell therapy for GVHD, transplantation, and autoimmune diseases.
    Nagamura-Inoue T, Ichimura S, Ogami K, Tojo A.
    Regulatory T cells harbored the immunosuppressive effects and were related to the pathogenesis of graft-versus-host disease (GVHD), rejection of organ transplantation and autoimmune disease. We developed the system of ex vivo expansion of CD25+FOXP3+regulatory T cells using mTOR inhibitor, from the small amount of CD4+peripheral blood and also cord blood (CB), to apply the immunological therapy.
    5. Research Cord Blood Stem Cell Bank/National BioResouce Project (NBRP) (IMSUT-Cell Resource Center):
    Nagamura-Inoue T, Ichimura S, Takahashi A. Hori A, Shimazu T, Ueda M.
    “Research Cord Blood Stem Cell Bank” (former named ‘Research Stem Cell Resource Bank’) was established supported by MEXT for the development of the medicine including Regenerative Medicine and drug discovery in Japan since 2004. Since 2012, July, this project has been incorporated in National BioResouce Project (NBRP). The research CB bank provides processed and cryopreserved CB units which are non-conforming for clinical use, to world-wide researchers via RIKEN Bioresource Center. Visit our website http://www.nbrp.jp/.
    6. Management of Institute of Medical Science, University of Tokyo-Cell Resource Center (IMSUT-CRC):
    Nagamura-Inoue T, Takahashi A., Shimazu T., Ogami K, Tojo A
    To promote the cell therapy in translational researches, IMSUT-Cell Resource Center (IMSUT-CRC) has been established in 1997 (originally called as Room for Clinical Cellular Technology (RCCT)). Until now, the following projects had implemented; 1) CB cell processing for banking(1997-2008) (for Tokyo Cord Blood Bank, Research cord blood stem cell bank, and related sibling donors), 2) Dendritic cell therapies (1998-2001), 3) Regenerative therapy of alveolar bone derived from bone marrow mesenchymal cells (2005-2011), 4) Gene therapy for renal cancer (1998), 5) CB and UC-MSCs banking (IMSUT-CORD) (2012-present), 6) Regenerative medicine for hemophilia arthropathy using autologous bone marrow-derived MSC (in preparation).

    セルプロセッシング・輸血部の研究一覧

    承認番号 研究課題名 備考
    30-30-B0719 頭頸部放射線障害に対する臍帯由来間葉系幹細胞療法の開発 2018/7/19-2023/3/31
    30-51-A1018 間葉系細胞を用いた骨・軟骨再生医療を目指した基盤研究 2018/10/18-2023/9/30
    30-55-A1127 自家周産期付属物由来細胞を活用した新規細胞治療法の開発 2018/11/27-2023-9-30
    26-30-0717 研究用ヒト臍帯血幹細胞の収集・保存・提供
    (ナショナルバイオリソースプロジェクト)
    2019-81-0319へ継続
    27-24-0819 ヒト臍帯血・臍帯由来細胞の新規凍害保護液を用いた保存に関する研究 H27.8.19-H33.3.31
    27-61-1223 脳神経障害に対する臍帯血・臍帯由来間葉系細胞を用いた新規治療法開発に向けた基盤研究 H27.12.23-H33.3.31
    29-28-A0722 臍帯血及び臍帯由来細胞等を用いた新規免疫細胞療法の開発 2017/7/22-2022/3/31
    29-73-A0219 細胞治療製品における病原微生物試験の確立に関する研究 2018/2/19-2023/3/31
    2019-21-0718 臍帯血・臍帯由来細胞中の幹細胞および脱分化能の検討 2019/7/18-2024/3/31
    2019-40-1017 効率的アフェレーシスと採取細胞の品質への影響因子の解析研究 2019/10/18-2022/9/30
    2019-81-0319 研究用ヒト臍帯血細胞の収集・保存・提供
    (ナショナルバイオリソースプロジェクト)
    2020/3/27-2025/3/31
    2019-79-0319 血友病性関節症に対する新規細胞治療の開発 2020/3/27-2025/3/31
    2019-80-0319 放射線障害に対する細胞治療の開発 2020/3/27-2025/3/31
    30-8-A0522 人工多能性幹(iPS)細胞を活用する疾患病態解明および治療法開発研究 2018/5/22-2023/3/31
    26-112-270402 血液疾患のゲノム解析研究 2015/4/2-2020/3/30
    →2020-1-0422へ継続
    29-40-B1005 医科学研究所血清バンクの構築 2017/10/5-2022/3/31
    2019-16-0718 腫瘍由来循環DNAを用いた移植後微小残存急性リンパ性白血病病変に関する多施設共同前方視的解析研究 2019/7/29-2022/3/31
    30-97-20190903 悪性腫瘍に対するネオ抗原ペプチドパルス樹状細胞を用いた個別化ワクチン療法の開発‐製法開発に関する研究‐ 2019/9/3-2024/3/31
    2019-53-1219 遺伝子検査余剰検体の医科研バンキング事業 2020/1/9-2024/12/31
    2020-1-0422 血液疾患の臨床ゲノム解析研究 2020/4/22-2025/3/31
    2019-76-0225 COVID-19:免疫機能不全者の抗体獲得率に関する疫学研究 2020/5/27-2022/9/30
    2020-13-0521 診療で用いるCOVID-19の抗体検査キットの精度調査 2020/5/27-2022/9/30
    2020-12-0527 新型コロナウィルス感染症(COVID-19)を対象とした、PCR検査法と血清抗体価の比較による疫学調査 2020/5/27-2025/3/31
    2020-16-0623 急性骨髄性白血病における免疫チェックポイント分子の発現と遺伝子/染色体異常との関連の解析と新規治療法の開発 2020/6/23-2024/3/31

    Publication

    英語論文

    1. Mukai T, Mori Y, Shimazu T, Takahashi A, Tsunoda H, Yamaguchi S, Kiryu S, Tojo A, Nagamura-Inoue T.Intravenous injection of umbilical cord-derived mesenchymal stromal cells attenuates reactive gliosis and hypomyelination in a neonatal intraventricular hemorrhage model. Neuroscience. Jul 4;355:175-187, 2017.
    2. Nagamura-Inoue T, Mukai T. Umbilical Cord is a Rich Source of Mesenchymal Stromal Cells for Cell Therapy. Current Stem Cell Research & Therapy, 11, 634-642,2016
    3. Itonaga H, Iwanaga M, Aoki K, Aoki J, Ishiyama K, Ishikawa T, Sakura T, Fukuda T, Najima Y, Yujiri T, Mori T, Kurokawa M, Nawa Y, Uchida N, Morishita Y, Hashimoto H, Eto T, Hirokawa M, Morishima Y, Nagamura-Inoue T, Atsuta Y, Miyazaki Y. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study. Leuk Res. 2015 Dec 24. doi: 10.1016/j.leukres.2015.12.009. [Epub ahead of print]
    4. Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K, Miyawaki S, Uchida N, Maeda T, Nagamura-Inoue T, Asou N, Morishima Y, Atsuta Y, Miyazaki Y, Kimura F, Kobayashi Y, Takami A, Naoe T, Kanda Y. Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. Eur J Haematol. Dec 18. doi: 10.1111/ejh.12723. [Epub ahead of print], 2015.
    5. Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, Najima Y, Fukuda T, Uchida N, Takahashi S, Nagamura-Inoue T, Morishima Y, Miyamura K. Japan Society for Hematopoietic Cell Transplantation, Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. Biol Blood Marrow Transplant. 2015 Oct 22. pii: S1083-8791(15)00676-X. doi: 10.1016/j. bbmt.2015.10.006. [Epub ahead of print], 2015.
    6. Mori J, Ishiyama K, Yamaguchi T, Tanaka J, Uchida N, Kobayashi T, Fukuda T, Kanamori H, Miyamura K, Takahashi S, Eto T, Hirokawa M, Mori S, Nagamura T, Atsuta Y, Takami A. Outcomes of allogeneic hematopoietic cell transplantation in patients with biphenotypic acute leukemia. Ann Hematol. 2015 Oct 26. [Epub ahead of print]
    7. Mukai T, Nagamura-Inoue T, Shimazu T, Mori Y, Takahashi A, Tsunoda H, Yamaguchi S, Tojo A. Neurosphere formation enhances the neurogenic differentiation potential and migratory ability of umbilical cord-mesenchymal stromal cells. Cytotherapy. 18:229-241, 2016.
    8. Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 51:43-50, 2016.
    9. Arai Y, Kanda J, Nakasone H, Kondo T, Uchida N, Fukuda T, Ohashi K, Kaida K, Iwato K, Eto T, Kanda Y, Nakamae H, Nagamura-Inoue T, Morishima Y, Hirokawa M, Atsuta Y, Murata M. Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 51:96-102, 2016.
    10. Nakane T, Fukuda T, Kanda J, Taniguchi S, Eto T, Ohashi K, Nakamae H, Kurokawa M, Mori T, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Murata M. Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant. Leuk Lymphoma. 56:2392-7, 2015.
    11. Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T, Miyamura K, Eto T, Kanamori H, Iwato K, Uchida N, Mori S, Nagamura-Inoue T, Ichinohe T, Atsuta Y, Teshima T, Murata M. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transplant. 50:559-65, 2015.
    12. He H. Nagamura-Inoue T., Takahashi A., Mori Y., Shimazu T., Tsunoda H., Tojo A. Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in Vitro, Int J Hematol..in press, 2015
    13. Shimazu T, Mori Y, Takahashi A, Tsunoda H, Tojo A, Nagamura- Inoue T, Serum- and Xeno-free Cryopreservation of Human umbilical cord tissue as mesenchymal stromal cell source, Cytotherapy, 17,593-600, 2015, DOI: http://dx.doi.org/10.1016/j.jcyt.2015.03.604
    14. Mori Y, Ohshimo J, Shimazu T, He H, Takahashi A, Yamamoto Y, Tsunoda H, Tojo A, Nagamura-Inoue T. Improved Explant Method To Isolate Umbilical Cord-derived Mesenchymal Stem Cells And Their Immunosuppressive Properties.  Tissue Eng Part C Methods. 21,1-6, 2014, DOI: 10.1089/ten.tec.2014.0385
    15. Konuma T, Ooi J, Uchida N, Ogawa H, Ohashi K, Kanamori H, Aotsuka N, Onishi Y, Yamaguchi H, Kozai Y, Nagamura-Inoue T, Kato K, Suzuki R, Atsuta Y, Kato S, Asano S, Takahashi S.Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. Haematologica. 99,e264-8,2014
    16. Ohashi K, Nagamura-Inoue T, Nagamura F, Tojo A, Miyamura K, Mori T, Kurokawa M, Taniguchi S, Ishikawa J, Morishima Y, Atsuta Y, Sakamaki H. Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. Int J Hematol. 100, 296-306,2014
    17. He H. Nagamura-Inoue T., Tsunoda H., Yuzawa M., Yamamoto Y., Yorozu P., Agata H., Tojo A. Stage-Specific Embryonic Antigen 4 in Wharton’s Jelly-derived mesenchymal stem cells is not a marker for proliferation and multipotency. Tissue Engineering., Tissue Eng Part A. 20,1314-24,2014. DOI: 10.1089/ten.tea.2013.0333
    18. Sakabe S, Takano R, Nagamura-Inoue T, Yamashita N, Nidom CA, Quynh Le MT, Iwatsuki-Horimoto K, Kawaoka Y . Differences in Cytokine Production in Human Macrophages and in Virulence in Mice Are Attributable to the Acidic Polymerase Protein of Highly Pathogenic Influenza A Virus Subtype H5N1. J Infect Dis. 207:262-71, 2013
    19. Ebihara Y, Takedani H, Ishige I, Nagamura-Inoue T, Wakitani S, Tojo A, Tsuji K. Feasibility of autologous bone marrow mesenchymal stem cells cultured with autologous serum for treatment of haemophilic arthropathy. Haemophilia. 19:e87-9, 2013.
    20. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le MQ, Nagamura-Inoue T, Horimoto T, Yamashita N, Kawaoka Y. Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. J Gen Virol. 92:1428-34, 2011
    21. Ishige I., Nagamura-Inoue T., Honda J.M, Harnprasopwat R., Kido M., Sugimoto M., Nakauchi H, Tojo A. Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton’s jelly explants of human umbilical cord. Int J Hematol, 90:261-9, 2009.
    22. Konuma T, Takahashi S, Ooi J, Tomonari A, Tsukada N, Kato S, Sato A, Monma F, Kasahara S, Nagamura-Inoue T, Uchimaru K, Iseki T, Tojo A, Yamaguchi T, Asano S. Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age. Ann Hematol. 88:581-8,2009.
    23. Nagamura-Inoue T, Kai S, Azuma H, Takanashi M, Isoyama K, Kato K, Takahashi S, Taniguchi S, Miyamura K, Aoki K, Hidaka M, Nagamura F, Tojo A, Fang X, Kato S; Japan Cord Blood Bank Network. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplant. 42:241-51, 2008
    24. Konuma T, Ooi J, Takahashi S, Tomonari A, Tsukada N, Kobayashi T, Sato A, Kato S, Kasahara S, Ebihara Y, Nagamura-Inoue T, Tsuji K, Tojo A, Asano S. Cardiovascular toxicity of cryopreserved cord blood cell infusion. Bone Marrow Transplant. 41:861-5.2008
    25. Nakayama S, Nagamura-Inoue T, Yokoyama K, Ohno K, Ooi J, Takahashi S, Uchimaru K, Iseki T, Tojo A. Cytogenetic remissions induced by interferon- and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Int J Hematol. 86:208-211, 2007.
    26. Nagamura-Inoue T, Kodo H, Takahashi T, Mugishima H, Tojo A, Asano S. Four cases of donor cell-derived AML following unrelated cord blood transplantation for adult patients: experiences of the Tokyo Cord Blood Bank. Cytotherapy. 4:1-2,2007
    27. Okada H, Nagamura-Inoue T, Mori Y, Takahash TA. Expansion of Valpha24Vbeta11 NKT cells from cord blood mononuclear cells using Interleukin-15, IL-7 and Flt3-L depends on monocytes. Eur J Immunol. 36:236-244, 2006
    28. Yasutake, M, Zheng Y, Nagamura-Inoue, T, Akagawa E, Tokushima Y, Terashima S, Takahashi TA. SCID-Repopulating activity of human umbilical cord blood-derived hematopoietic stem/progenitor cells in a nonobese diabetic/Schi-SCID mice serial xenoransplantation model and immune cell activities in vitro: a comparative study of the filter method and the HES method, Transfusion. Transfusion. 45:1899-908, 2005.
    29. Nagamura-Inoue T, Mori Y, Zheng Y, Watanabe N, Takahashi TA. Differential expansion of umbilical cord blood mononuclear cell derived natural killer cells dependent on the dose of Interleukin 15 with Flt3L. Exp Hematol 32:202-209, 2004.

    欧文国際雑誌に掲載された総説論文

    1. 1) Nagamura-Inoue T., and He H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility, World J Stem Cells 6,195-202, 2014

    和文論文

    1. Tanosaki R., Muroi K., Nagamura-Inoue T., Ishida A., Mizuta S., Maekawa T., Ito T., Kishino K., Uemura T., Takahashi AT., Ohto H. for the Cell Processing Guideline Working Group of the Japan Society of Transfusion Medicine and Cell Therapy (JSTMCT). Guideline for processing cellular therapy products routinely used for hematopoietic stem cell transplantation in Japan. The Japan Society of Transfusion Medicine and Cell Therapy.(日本輸血・細胞治療学会誌(報告)), 57,184-187, 2011
    2. 2) 臍帯血単核球分離における採取後経過時間と保管温度条件の影響の検討   湯沢美紀, 長村(井上)登紀子, 石下郁夫, 尾上和夫, 田村友樹, 高橋敦子,幸道秀樹,山口暁, 東條有伸 Miki Yuzawa , Nagamura-Inoue T, Ikuo Ishige , Kazuo Ogami, Tomoki Tamura, Atsuko Takahashi, Hideki Kodo, Satoru Yamaguchi, and Arinobu Tojo, Time from cord blood collection to processing and temperature influence the quality of mononuclear cell products isolated using a density-gradient protocol., The Japan Society of Transfusion Medicine and Cell Therapy.(日本輸血・細胞治療学会誌), 57,139-145, 2011
    3. Ikeda K., Nagamura-Inoue T., Kai S., Fujii Y., Ozaki S., Sagawa K., Takamatsu J., Takahashi K., Ohto H.. Questionnaire surveys on cell processing in Japan by the Japanese Society of Transfusion Medicine and Cell Therapy/Japanese Association of Medical Technologists(2007) and by Working Group for Adverse Events of the Transfusion Conference of the University Hospitals(2006)., Japan J. Transfusion and cell Therapy, (日本輸血・細胞治療学会誌),55,397-404,2009 

    学会発表

    国内

    1. 長村登紀子, 臍帯由来間葉系細胞、ランチョンセミナー 第14回日本再生医療学会総会(横浜)2015/3/20
    2. 島津貴久、森有加、高橋敦子、向井丈雄、角田肇、東條有伸、長村登紀子, 間葉系細胞のソースとなる臍帯の凍結方法の開発, 第14回日本再生医療学会総会(横浜)2015/3/21
    3. 島津貴久、森 有加、中井未来、高橋敦子、何海萍、角田 肇、東條有伸、長村登紀子「凍結臍帯組織からの間葉系幹細胞分離の検討」, 日本炎症再生医学会総会 (沖縄)2014
    4. 長村(井上)登紀子, 何 海萍, 森 有加, 高橋 敦子, 山本由紀,島津貴久, 中井未来, 東條 有伸, 臍帯血・臍帯由来間葉系幹細胞のセミパブリックバンク樹立について, 第62回日本輸血・細胞治療学会(奈良)2014/5/16
    5. He H, Nagamura-Inoue T, Tsunoda H, Takahashi A, Yamamoto Y, Mori Y, and Tojo A. The Immunosupressive Effect of Wharton’s Jelly Mesenchymal Stem Cells for the treatment of GVHD, 第76日本血液学会学術集会総会 (大阪)2014/11/1
    6. 何 海萍, 長村登紀子, 角田肇, 東條有伸ら.  SSEA4 is not a marker for proliferation and pluripotency in Wharton's Jelly-derived MSCs, 臍帯由来間葉系幹細胞におけるSSEA4発現の意義ついて, 第75日本血液学会学術集会総会(北海道) 2013/10/11
    7. 長村登紀子、内丸薫、高橋聡、大井淳、加藤せい子、河北敏郎、大野伸広、湯地晃一郎、東條有伸, 当院における輸血後鉄過剰症診療の現状Current Clinical Practice in Post-transfusion Iron Overload in IMSUT Hospital, 第75日本血液学会学術集会総会 (北海道) 2013/10/12
    8. 長村登紀子、岸野光司、上村知恵, 造血細胞移植に必要な細胞処理・検査に関する技術講習会;こんな時どうする?Q and Aテクニカルセミナー第61回日本輸血・細胞治療学会(横浜)2013/5/16
    9. 長村登紀子、何海萍、東條有伸. 臍帯由来間葉系幹細胞の分離とその応用について 第34回日本炎症・再生医学会(京都) 2013/7/2
    10. 何 海萍, 長村登紀子, 角田肇, 東條有伸ら. Characterization of primitive markers in human umbilical cord-derived mesenchymal stem cells臍帯由来間葉系幹細胞における未熟細胞マーカーの解析 第74回日本血液学会学術集会総会 2012/10/19
    11. 山本由紀, 長村登紀子, 角田肇, 東條有伸ら. mTOR inhibitorの制御性T細胞の誘導増幅に及ぼす影響 The influence of mTOR inhibitor on inducible regulatory T cells 第74回日本血液学会学術集会総会 2012/10/20
    12. 長村登紀子, 小林誠一郎,尾上和夫,東條有伸, 第73回日本血液学会総会 OS-3-36 臍帯血からの制御性T細胞の誘導増幅による免疫抑療法の開発 京都 2011年10月16日
    13. 長村登紀子、尾上和夫、横山和明、東條有伸, 制御性T細胞の誘導増幅による免疫抑制療法の基礎的開発, Immunosuppressive therapy with ex vivo induction and expansion of regulatory T cells第72回日本血液学会 総会 (京都、2010年10月)
    14. 幸道秀樹、星野 茂角、長村(井上)登紀子 ,麦島秀雄、青木繁之, (東京臍帯血バンク)東京臍帯血バンクより供給した1000例の臍帯血移植の解析(第1報, 第58回日本輸血・細胞治療学会総会, 名古屋 2010年5月
    15. 臍帯血単核球分離における採取後の経過時間の影響, 湯沢美紀,長村(井上)登紀子,石下郁夫,尾上和夫,高橋敦子,幸道秀樹,東條有伸、第58回日本輸血・細胞治療学会総会, 名古屋 2010年
    16. 長村登紀子, 造血細胞移植における細胞検査, 第17回日本輸血・細胞治療学会秋季シンポジウム, 名古屋,2010年
    17. 長村登紀子.国内外の臍帯血や造血幹細胞処理基準からふり返ってみた院内細胞処理基準における課題;ワークショップ日本輸血・細胞治療学会, 2009
    18. 長村登紀子、尾上和夫、横山和明、伊東清子、石下郁夫、小林誠一郎、東條有伸, 制御性T細胞の選択的増幅によるGVHD制御法の開発、第70回 日本血液学会 総会(京都、2008年10月)
    19. 石下 郁夫、長村―井上登紀子、本田 雅規、木戸道子、杉本充弘、中内啓光、東條有伸:臍帯由来間葉系幹細胞分離とその多分化能に関する検討; 第69回 日本血液学会 総会(横浜、2007年10月)
    20. 中山紳、長村―井上登紀子、横山 和明、石下 郁夫、尾上和夫、二見 宗孔、小林誠一郎、大野伸広、大井淳、高橋 聡、内丸薫、東條有伸 慢性骨髄性白血病―細胞遺伝学的官界例の免疫学的解析:インターフェロン群とイマチニブ群の比較; 第69回 日本血液学会 総会(横浜、2007年10月)
    21. 長村―井上登紀子、幸道秀樹、麦島秀雄、崔硯、高橋恒夫、浅野茂隆:東京臍帯血バンクからの臍帯血移植における生着に関する予後因子の解析と動向(II) 第68回 日本血液学会 総会(福岡、2006年10月)
    22. 第53回日本輸血学会総会 シンポジウム: 造血幹細胞移植における造血幹・前駆細胞の測定について、2005
    23. 長村登紀子;臍帯血バンク細胞処理からふり返ってみた院内細胞処理基準作成の課題、第126回日本輸血細胞治療学会関東甲信越支部例会、2008
    24. 長村登紀子. 洗浄血小板の適正な院内調製・品質管理; ワークショップ日本輸血・細胞治療学会2008

    海外

    1. Yuka Mori, Tokiko Nagamura-Inoue, Jun Ohshimo, Takahisa Shimazu, Haiping He, Astuko Takahashi, Hajime Tsunoda, and Arinobu Tojo、IMPROVED EXPLANTS METHOD TO ISOLATE UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS AND THEIR IMUUNOSUPPRESIVE PROPERTIES (POSTER), ISCT, PARIS, 2014/4/23-27
    2. H He,, T Nagamura-Inoue, H Tsunoda, Y Yamamoto, Y Mori, and A Tojo, The Immunosupressive Effect Of Wharton’s Jelly-Derived Mesenchymal Stem Cells in vitro, ASH in Asia, Singapore, Mar. 29, 2014
    3. H He,, T Nagamura-Inoue, H Tsunoda, Y Yamamoto, Y Mori, and A Tojo, The Immunosupressive Effect Of Wharton’s Jelly-Derived Mesenchymal Stem Cells in vitro, 55th ASH annual meeting, New Orleans, Dec. 8, 2013
    4. R. Tanosaki, Y. Okuyama, T. Iseki, M. Handa, S. Kino, T. Kumazawa, S. Yoshida, K. Haraguchi, N. Schimizu, S. Sakai, N. Watanabe, T. Uemura, K. Ikuta, Y. Kawahara, K. Muroi, T. Nagamura-Inoue, M. Takanashi, for the HPC Study Group, the Japan Society of Transfusion Medicine and Cell Therapy (JSTMCT), ASH meeting, New Orleans, Dec. 7, 2013
    5. H. Itonaga, M. Iwanaga, K. Aoki, J. Aoki, K. Ishiyama, T. Kobayashi, T. Sakura, T. Fukuda, T. Yujiri, M. Hirokawa, Y. Morishima, T. Nagamura-Inoue, Y. Atsuta, T. Ishikawa, Y. Miyazaki. Influence of acute and chronic graft-versus-host disease on outcome after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia, New Orleans, Dec. 7, 2013
    6. Nagamura-Inoue T, Yamamoto Y, Kobayashi S , Yuzawa M, He H, Tsunoda H, and Tojo A. Impact of mTOR inhibitor, Everolimus on inducible regulatory T cells Derived from Cord Blood, International Society of Cellular Therapy (ISCT) Annual meeting, New Zealand, 2013
    7. Tokiko Nagamura-Inoue, Seiichiro Kobayashi, Kazuo Ogami, Yuki Yamamoto, Kiyoko Izawa, and Arinobu Tojo, The Significance of mTOR Inhibitor, Everolimus in TGF-β-Induced Regulatory T cells from Cord Blood., 2180, American Soceity of Hematology Annual meeting, San Diego Convention Center, USA, Dec. 11, 2011
    8. Murata M, Taniguchi S, Nagamura-Inoue T, Kato K, on behalf of the Japan Cord Blood Bank Network. Cord blood transplantation for myelofibrosis: a retrospective analysis from the Japan Cord Blood Bank Network. The 36th annual meeting of the European Group for Blood and Marrow Transplantation, in Vienna, Austria. March 2010
    9. Morio T, Daisuke Tomizawa, Yoshiko Atsuta, Tokiko Nagamura-Inoue, Koji Kato, Tadashi Ariga, Keisei Kawa, Kazutoshi Koike, Hisamichi Tauchi, Michiko Kajiwara, Toshirou, Hara, and Shunichi Kato. Unrelated Umbilical Cord Blood Transplantation for Patients with Primary Immunodeficiency: A Report From the Registry of the Japan Cord Blood Bank Network:, 52nd ASH annual meeting, Orlando, USA, Dec. 6, 2010
    10. S.Kurosawa, K.Yakushijin, T.Yamaguchi, Y. Atsuta, T.Nagamura-Inoue, H.Akiyama, S. Taniguchi, K. Miyamura, S. Takahashi, T. Eto, Y. Morishima, H. Sakamaki and T. Fukuda. Changes In Incidence and Causes of Non-Relapse Mortality (NRM) After Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Are Transplants Improving? 52nd ASH annual meeting, Orlando, USA, Dec. 7, 2010
    11. Ikuo Ishige, Tokiko Nagmaura-Inoue, Masaki J. Honda, Arinobu Tojo, Compatrative study of mesehchymal stem cells derived from arterial, venous, and Wharton’s jelly explants of human umbilical cord., International Society of Cell Therapy, Annual meeting, Philadelphia, 2010
    12. Tokiko Nagamura-Inoue, MD., PhD.1,2, Shunro Kai, MD., PhD.2*, Minoko Takahashi, MD.,PhD.2*, Koji Kato, MD., PhD.2, Keiichi Isoyama, MD., PhD.2*, Masatoshi Jinzen, MD.,PhD.2*, Hiroshi Azuma, MD., PhD.2*, Shuichi Taniguchi, MD., PhD.2, Masao Nakabayashi,MD., PhD.2* and Shunichi Kato, MD., PhD.2*. Unrelated Cord blood transplantation for the patients with CML, a Japan Cord Blood Bank Network Analysis, Poster session, 48 th ASH meeting, 2006
    13. Tokiko Nagamura-Inoue, MD., PhD.1,7, Hideki Kodo, MD., PhD.2,7*, Tsuneo A. Takahashi,MD., PhD.3,7*, Hideo Mugishima, MD., PhD.4,7, Arinobu Tojo, MD., PhD.1,7 and Shigetaka. Asano, MD., PhD Four cases of donor cell-derived acute myeloid leukemia following unrelated cord blood transplantation for adult patients; Tokyo cord blood bank experiences, Poster session, 48 th ASH meeting
    14. T. Nagamura-Inoue, K. Ogami1, K. Yokoyama, S. Nakayama, I. Ishige, S. Izawa, S. Kobayashi, A. Tojo, LARGE SCALE EX VIVO EXPANSION OF CD4+CD25+FOXP3+ REGULATORY T CELLS FROM PERIPHERAL BLOOD, International Society of Cellular Therapy (ISCT) Annual meeting, Florida, 2008
    15. Tokiko Nagamura-Inoue, MD, PhD, Kazuo Ogami, Kazuaki Yokoyama, Kiyoko Izawa, Seiichiro Kobayashi, Shin Nakayama, Ikuo Ishige, Yusuke Inoue, Jun Ooi, Kaoru Uchimaru, Satoshi Takahashi and Arinobu Tojo, Large Scale Selective Ex Vivo Expansion of CD4+CD25+FOXP3+ Regulatory T Cells from Peripheral Blood, American Society of Hematology, Annual meeting, 2008